Intervention review
A review of the effects of an intervention on pre-specified outcomes, with a quantitative synthesis where the contributing studies are sufficiently similar.
Reviews
-
In adults who have lost weight during treatment with an incretin receptor agonist, what happens to body weight after treatment is withdrawn?
Moderate09 Mar 2026 -
In adults with type 2 diabetes and chronic kidney disease, what is the effect of a glucagon-like peptide-1 receptor agonist on kidney outcomes?
High07 May 2026 -
In adults with type 2 diabetes, does tirzepatide achieve greater glycaemic and weight effect than semaglutide?
High26 Apr 2025 -
In adults with obesity and without type 2 diabetes, what is the effect of a glucagon-like peptide-1 receptor agonist compared with placebo on percentage change in body weight at the primary analysis timepoint?
High23 May 2025 -
In adults at elevated cardiovascular risk, what is the effect of a glucagon-like peptide-1 receptor agonist compared with placebo on major adverse cardiovascular events?
High24 Oct 2025 -
What is the effect of an amylin receptor agonist alone and in combination with a glucagon-like peptide-1 receptor agonist on body weight?
Moderate10 Aug 2026 -
What is the evidence for thymic peptides in chronic viral hepatitis, sepsis and non-specific immune support?
Low17 Jun 2025 -
Does the cardiovascular effect of a glucagon-like peptide-1 receptor agonist established in secondary prevention extend to a primary-prevention population?
Moderate08 Apr 2026 -
In adults with metabolic dysfunction-associated steatohepatitis, do incretin receptor agonists improve histological outcomes, and does histological improvement predict clinical benefit?
Moderate12 Jan 2026 -
In adults with heart failure with preserved ejection fraction and obesity, what is the effect of an incretin receptor agonist on symptoms and on heart-failure events?
Moderate11 Oct 2024 -
In adults with obesity and moderate to severe obstructive sleep apnoea, what is the effect of a pharmacological weight-reducing agent on the apnoea–hypopnoea index?
Moderate25 Feb 2026 -
In adolescents with obesity, what is the effect of an incretin receptor agonist on body-mass index, and what is known about growth, bone accrual and pubertal outcomes?
Moderate09 Jan 2026 -
What randomised evidence supports mitochondria-targeted peptides in primary mitochondrial disease and in age-related functional decline?
Low25 Jul 2025 -
In the population defined for obesity and overweight in adults, is the effect of Tirzepatide maintained across the full duration of the contributing trials?
High15 Apr 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Tirzepatide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High04 Aug 2025 -
In the population defined for obesity and overweight in adults, is the effect of Semaglutide maintained across the full duration of the contributing trials?
High01 Aug 2025 -
In the population defined for obesity and overweight in adults, what is the effect of Semaglutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High22 Oct 2025 -
In the population defined for type 2 diabetes mellitus, is the effect of Dulaglutide maintained across the full duration of the contributing trials?
High12 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Dulaglutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High14 Apr 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Semaglutide maintained across the full duration of the contributing trials?
High18 Feb 2026
page 1 of 4